Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 9/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 6/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22035471 | 0.82 | PTGS2 (0.41) | IDO1PTGS2PDE3BPDE3A | |
| SCHEMBL16009749 | 0.82 | HTR2A (0.39) | HTR2AHTR2CCRHR1 | |
| SCHEMBL25745801 | 0.82 | ACHE (0.41) | HTR2AHTR2CNR3C1NR3C2PTGS2 | |
| SCHEMBL19871663 | 0.81 | HTR2A (0.38) | HTR2AHTR2CNR3C1NR3C2PTGS2 | |
| SCHEMBL25745865 | 0.79 | HTR2A (0.37) | HTR2AHTR2CPTGS2PDE3BPDE3A | |
| SCHEMBL16257102 | 0.77 | TAAR1 (0.38) | PTGS2PDE3BPDE3A | |
| SCHEMBL21957007 | 0.74 | EPAS1 (0.41) | HTR2AHTR2CIDO1NR3C1NR3C2 | |
| SCHEMBL30901285 | 0.74 | EPAS1 (0.41) | HTR2AHTR2CIDO1NR3C1NR3C2 | |
| SCHEMBL21264177 | 0.73 | ATM (0.43) | HTR2AHTR2CPGR | |
| SCHEMBL22037341 | 0.71 | HTR2A (0.36) | HTR2AHTR2CIDO1NR3C2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | HTR2A 1691/4885HTR2C 804/4885IDO1 864/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | HTR2A 1691/4885HTR2C 804/4885IDO1 864/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | HTR2A 1691/4885HTR2C 804/4885IDO1 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.